Lymphoma
The lymph in the human body is actually complicated. Lymphoma is the fastest and the highest death in malignant tumors, because the lymphatic system of the human body has a great effect on the whole body. Once cancer cells appear, they will spread along the blood , It will be spread all over the body, which makes the treatment more difficult. Lymphoma targeted drugs are not completely free of side effects. The patients who use them must carefully observe their changes bit by bit and communicate with the doctor in time to be able to reduce.
Ndiyo here yakanangwa mishonga ye lymphoma inoshanda?
Early malignant lymphoma is actually lymphoma. When using targeted drugs, you must first perform genetic testing on the patient. When you find the corresponding targeted drugs, the targeted drugs have a direct killing effect on cancer cells. The advantage is that the damage to normal cells is not too great. Although there are side effects and drug resistance, it depends on the patient’s physical function, good physical fitness, high immunity, and the best therapeutic effect. Therefore, patients with lymphoma have to find ways to improve their immune function and enhance their resistance to tumors while using targeted drugs.
Targeted drug therapy affects the biological processes of cells, acting in different ways, preventing cancer cells from growing or dividing, causing cancer cells to die or using their own immune system to help the body kill cancer cells. Compared with chemotherapy, targeted drugs can act more precisely on lymphoma cells and reduce the impact of treatment on healthy cells, thereby reducing the side effects of treatment while being more effective.
Ndezvipi zvakanangwa zvinodhaka zve lymphoma?
Rituximab is the first targeted immunotherapy drug used to treat lymphoma. There are many other targeted drugs for the treatment of patients with lymphoma, some have been approved for marketing, and many drugs are still in clinical trials.
1. Chronic lymphocytic leukemia (CLL) / small lymphocytic leukemia (SLL)
• Ibrutinib (Ibutinib, Imbruvica Eke)
• Idelalisib (Edelalis, Zydelig)
• Obinutuzumab (Atoruzumab, Gazyva)
• Rituximab (rituximab, Rituxan merova)
2. Ganda (ganda) T cell lymphoma
• Brentuximab Vedotin (Bentuximab, Adcetris)
3. Kuparadzira yakakura B-cell lymphoma
• Rituximab (rituximab, Rituxan merova)
4. Follicular lymphoma
• Idelalisib (Edelalis, Zydelig)
• Obinutuzumab (Atoruzumab, Gazyva)
• Rituximab (rituximab, Rituxan merova)
• Ibritumomab Tiuxetan (Timobizumab, Zevalin)
5. Classic Hodgkin lymphoma
• Brentuximab Vedotin (Bentuximab, Adcetris)
• Nivolumab (Navuliu monoclonal antibody, Opdivo)
• Pembrolizumab (Pambrolizumab, Keytruda)
6. Kunyanya mediastinal B-cell lymphoma
• Rituximab (rituximab, Rituxan merova)
7. Mantle sero lymphoma
• Bortezomib (bortezomib, Velcade Velcade)
• Ibrutinib (Ibutinib, Imbruvica Eke)
• Lenalidomide (Lenalidomide, Revlimid)
• Temsirolimus (yesirolimus, Torisel)
8. Systemic anaplastic hombe cell lymphoma
• Brentuximab Vedotin (Bentuximab, Adcetris)
Iko hakuna chiyero chakajairika pamutengo we lymphoma yakanangwa zvinodhaka
Lymphoma yakanangwa mishonga inowanzo rituximab (rituximab jekiseni), nzira yekurapa ingangoita zviuru gumi kana makumi maviri. Izvo zvakanangana zvinoenderana nemamiriro emurwere. Kana pasina kupokana nemishonga, unogona kuenderera mberi kuitora. Kana paine mhedzisiro kana kusagadzikana kwemushonga, unofanirwa kumbomisa kana kushandisa dzimwe nzira dzekurapa. Naizvozvo, mutengo hauna kugadziriswa. Pachave neshanduko.
Ropa rakachena mumuviri rinotarisirwa nehematopoietic system, uye iyo lymphatic system ndiyo maneja. Kune akawanda zvigadzirwa zvemagetsi izvozvi, uye radiation iri kwese kwese, uye kune hutachiona hutachiona hunoonekwa chero nguva. Izvi zvinouraya lymphoma Incentives, iwe unofanirwa kubhadhara zvakanyanya kuti ugare kure nema lymphomas muhupenyu, uye kusarudzwa kwemishonga yakanangwa kune lymphomas haina kuita zvisina kujairika.
